Rabbit Monoclonal NCR1 antibody. Suitable for Flow Cyt and reacts with Mouse samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Flow Cyt | WB | ICC/IF | IHC-P | IP | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Mouse | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/400 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human, Rat | Dilution info - | Notes - |
Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.
CD335, Ly94, Ncr1, Natural cytotoxicity triggering receptor 1, Activating receptor 1, Lymphocyte antigen 94, Natural killer cell p46-related protein, mAR-1, NK-p46, NKp46, mNKp46
Rabbit Monoclonal NCR1 antibody. Suitable for Flow Cyt and reacts with Mouse samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
NCR1 also known as NKp46 is a receptor mainly expressed on the surface of natural killer (NK) cells. Its primary role involves recognizing and binding to ligands present on target cells including tumor cells and virus-infected cells. NCR1 initiates the activation of NK cells leading to the destruction of these abnormal cells. The NCR1 protein has a molecular weight of approximately 46 kDa and is a part of the immunoglobulin superfamily. NCR1 is mainly expressed in the immune system specifically on NK cells which are an important component of the innate immune response.
The function of NCR1 involves the recognition of stressed transformed or infected cells marking them for elimination by NK cells. It does not typically function as a part of a complex; rather it serves a somewhat autonomous role in cell signaling. However its interaction with other receptors on NK cells including DAP12 enhances its signaling capabilities. Through the activation of cascades NCR1 promotes the release of cytotoxic granules and the production of cytokines therefore mediating the immune response.
NCR1 plays a significant role in the regulation of immune surveillance pathways. It is involved in the recognition and elimination pathways that modulate the immune response against infected or cancerous cells. NK cells with NCR1's involvement interact with receptors like NKG2D adjusting the NK cell's cytotoxic activity. These interactions coordinate the broader immune response important for innate immunity effectively bridging innate and adaptive immunity by influencing other immune cells.
NCR1 has been implicated in cancer and infectious diseases. In cancer altered expression or dysfunction of NCR1 may contribute to the evasion of immune surveillance by tumor cells potentially leading to tumor progression. Studies have shown reduced NKp46 expression in some cancerous states linking it to poor prognosis. In infectious diseases NCR1 plays a role in targeting virus-infected cells and its dysfunction can result in reduced effectiveness in clearing viral infections. Interactions with viral envelope proteins can interfere with NCR1 activity exemplifying its importance in antiviral defense mechanisms.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of Mouse splenocytes cells labelling NCR1 with ab300044 at 1/500 dilution (0.1μg)/ Right compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Left isotype control. Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/2000 dilution was used as the secondary antibody. Cells were stained with rabbit IgG or ab300044. Then stained with anti-CD49b conjugated to PE. Gated on viable cells.
Flow cytometric analysis of Mouse splenocytes cells labelling NCR1 with ab300044 at 1/500 dilution (0.1?g)/ Right compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Left isotype control. Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/2000 dilution was used as the secondary antibody. Cells were stained with rabbit IgG or ab300044. Then stained with anti-CD49b conjugated to PE. Gated on viable cells.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com